引用本文:马 力,潘金兰,吴亚芳,薛永权.成人急性髓细胞性白血病患者的WHO分型与FAB分型的比较研究[J].大连医科大学学报,2009,31(5):549-552.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 次   下载 本文二维码信息
码上扫一扫!
分享到: 微信 更多
成人急性髓细胞性白血病患者的WHO分型与FAB分型的比较研究
马 力1, 潘金兰2, 吴亚芳2, 薛永权2
1.大连市友谊医院 肿瘤血液科,辽宁 大连 116001;2.苏州大学 第一附属医院 血液病研究所,江苏 苏州 215006
摘要:
[目的] 比较急性髓细胞性白血病(acute myeloid leukemia,AML)患者FAB分型和WHO分型的优缺点。[方法]联合应用骨髓细胞形态学、免疫表型检测、常规细胞遗传学技术、多重RT-PCR技术对94例患者进行检测。分别对这94例患者进行FAB分型及WHO分型。[结果] WHO分型:AML:(1)伴有再现性遗传学异常的AML 42例;(2)伴有多系病态造血的AML 3例;(3)治疗相关性AML和MDS 0例;(4)无法按上述分型的白血病(NOC-AML)45例。FAB分型为 MDS:MDS-RAEB 1例、MDS-RAEBT 7例。AML M0 3例、M1 10例、M2 33例、M3 13例、M4 6例、M5 17例、M6 4例。对90例WHO分型诊断的AML患者进行预后评估:化疗前白细胞计数、化疗1、2次是否CR及遗传学异常对预后有影响。[结论]WHO分型全面地包括了AML的类型(原发性AML、MDS相关性AML、治疗相关性AML);提高了遗传学检测的重要性;同时将MDS-RAEBT纳入AML范围,给予MDS-RAEBT患者及时的治疗。应推广WHO分型,但以形态学为基础的FAB分型仍不可缺少。
关键词:  急性髓细胞性白血病  遗传学异常  WHO分型  FAB分型
DOI:10.11724/jdmu.2009.05.12
分类号:R733.71
基金项目:
Comparison between WHO-classification and FAB subtypes in adult acute myeloid leukemia patients
MA Li1, PAN Jin-lan2, WU Ya-fang2, XUE Yong-quan2
1.The Friendship Hospital of Dalian, Dalian 116001, China;2.The First Affiliated Hospital of Suzhou University, Suzhou 215006, China
Abstract:
[Objective] The comparison between the clinical practicability of the French-American-British (FAB) classification and the World Health Organization (WHO) classification of the acute myeloid leukemia (AML) was analyzed. [Methods] Specimens from 94 AML patients were diagnosed by bone marrow morphologic analysis, immunophenotypic, conventional cytogenetics and multiplex Reverse Transcription - Polymerase chain reaction. Patients were classified according to the FAB subtypes and the WHO subtypes. [Results] Using the WHO proposal, 42 patients had AML with recurrent genetic abnormalities. 3 patients had AML with multilineage dysplasia and 45 patients had WHO unclassified. According to FAB, 1 patients had myelodysplastic syndromes refractory anemia with excess of blasts (MDS-RAEB), 7 with refractory anemia with excess of blasts in transformation (MDS-RAEBT). AML-M0 to M6 were 3,10,33,13,6,17 and 4, respectively. [Conclusion] Our results indicate WHO classification that covers all AML subtypes, such as primary AML, MDS-related AML and therapy-related AML, enhances the importance of the cytogenetics, and includes the MDS-RAEBT subtype. But cytomorphology classification according the FAB criteria is still necessary for the diagnosis of AML.
Key words:  acute myeloid Leukemia  Cytogenetics  WHO classification  FAB classification